62 results about "Triglyceride level" patented technology

The invention provides a fat-reducing composition based on an agaricus bisporus extract as well as a preparation method and application of the fat-reducing composition, and belongs to the technical field of nutrition and health care. The fat-reducing composition comprises the following raw materials in parts by weight: 10-30 parts of an agaricus bisporus extract, 5-15 parts of a green tea extract, 5-15 parts of bitter gourd peptide, 3-10 parts of seaweed meal and 10-30 parts of resistant dextrin. The agaricus bisporus extract disclosed by the invention can regulate intestinal flora and promote fat metabolism; tea polyphenol in the green tea extract can inhibit fat synthesis and promote fat oxidation; momordica charantia peptide has an obvious hypoglycemic effect; the seaweed meal (containing fucoxanthin) has the effects of burning fat cells and eliminating fat accumulation; the resistant dextrin is used as dietary fiber, so that satiety is increased, and caloric intake is reduced. The raw materials cooperate with each other, so that the composition has better fat-reducing and weight-reducing effects, and the total cholesterol and triglyceride levels are reduced.

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

The present invention addresses the problem of defining physiological significance and functions such as the influence of nicotinamide mononucleotide (NMN) contained in breast milk on the development of children. A composition for improving the athletic ability of a child is provided comprising a precursor of NAD. The improvement in athletic ability is preferably any one selected from the group consisting of promotion of skeletal muscle development and improvement in activity. A composition for reducing triglyceride levels in the blood of a child is provided comprising a precursor of NAD. A composition for reducing the blood glucose level in a child is provided comprising a precursor of NAD. A composition for inhibiting fat accumulation in children is provided, comprising a precursor of NAD.

The present invention discloses applications and methods of Leuconostoc mesenteroides, relating to the field of microbial technology. Leuconostoc mesenteroides can be used to prepare phytic acid and improve non-alcoholic fatty liver disease, increased liver weight, elevated blood lipids, elevated blood sugar, elevated serum lipopolysaccharide levels, elevated serum insulin levels, inflammatory responses, and elevated triglyceride levels in the liver caused by a high-fat, high-sugar diet, and inhibit the release of the pro-inflammatory cytokine lipopolysaccharide.

An apparatus for measuring a triglyceride level includes: a sensor including: a plurality of peripheral light sources disposed at a periphery thereof, the plurality of peripheral light sources being configured to emit light toward an object, and a plurality of detectors each disposed at predetermined distances from the respective peripheral light sources of the plurality of peripheral light sources, the plurality of detectors being configured to detect optical signals reflected from or scattered by the object. The apparatus also includes a processor configured to selectively drive the plurality of peripheral light sources to obtain features based on the detected optical signals, and to measure the triglyceride level based on the obtained features.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The present invention provides a method for preparing an animal model of insulin resistance and abnormal glucose metabolism caused by mild to moderate hypertriglyceridemia, by injecting poloxamer 407 solution into the mouse peritoneal cavity at a dose of 25-100 mg per kilogram of mouse, administering the drug once every other day for 12 consecutive weeks, and continuously monitoring blood lipid and blood glucose levels. The preferred dose of the present invention is 75 mg per kilogram of mouse. The present invention also provides the use of the animal model in screening and preparing drugs for treating insulin resistance and abnormal glucose metabolism caused by mild to moderate hypertriglyceridemia. The present invention simulates insulin resistance and abnormal glucose metabolism directly caused by mild to moderate hypertriglyceridemia. Compared with traditional high-fat diets or gene knockout models, triglyceride levels are precisely regulated by chemical intervention, avoiding factors such as obesity and inflammation and the risk of genetic manipulation, and having high controllability and efficiency.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The invention discloses application of physcion in preparation of a medicine for reducing liver cell lipid deposition, and particularly relates to application of physcion in preparation of a medicine for preventing and treating lipid deposition fatty liver. In-vitro cell experiments prove that the physcion shows low toxicity and a wide safety range in a human normal hepatocyte line THLE3, a human hepatoma cell line HepG2 and a mouse normal hepatocyte line AML12, and can obviously reduce the level of oleic acid-induced intracellular triglyceride in a dose-dependent manner, so that the physcion can be used for preparing a medicine for treating liver cancer. Oil red O staining results also visually show that lipid droplet accumulation in cells can be effectively reduced; according to the invention, the technical prejudice that the emodin monomethyl ether is regarded as a potential hepatotoxic component in the prior art is overcome, a safe and effective new choice is provided for the treatment of the lipid deposition fatty liver, and the pharmaceutical composition has a wide clinical application prospect.

The invention discloses a strain for regulating and controlling intestinal fatty acid absorption as well as a screening method and application thereof. The screening method of the bacterial strain comprises the following steps: (1) carrying out intragastric administration on an SPF-level mouse by 100 mu L of a wild boar excrement suspension with the concentration of 10g / 100mL to colonize a wild boar excrement flora; 2) performing 16S rRNA sequencing to detect differential intestinal flora, and detecting and analyzing the difference of relative abundance of each species through a Kruscal-Wallis rank sum to obtain a strain which is in negative correlation with fatty acid metabolism (including but not limited to a plurality of indexes such as weight, adipose tissue quality, serum total triglyceride level, serum total cholesterol level and the like). The bacterial strain Rombout ilealis is preserved in the China Center for Type Culture Collection, the preservation date is September 12, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) M 20252008. The invention relates to a feed probiotic additive for regulating and controlling intestinal fatty acid absorption. The functional effect of R.ilealis in lipid metabolism is provided for the first time, and a new probiotic screening method is provided for controlling absorption of fatty acid in the intestinal tract.

The present invention relates to the use of Akkermansia muciniphila in the preparation of a pharmaceutical composition for improving alcoholic liver dysfunction. The Akkermansia muciniphila is Akkermansia muciniphila AM06, Akkermansia muciniphila AM02, or a combination of the two; wherein the deposit number of AM06 is CGMCC No. 22793, and the deposit number of AM02 is CGMCC No. 22794. Improving alcoholic liver dysfunction includes preventing and treating alcoholic fatty liver. In this application, liver function indicators (such as ALT and AST) can be improved by reducing triglyceride levels and total cholesterol in the liver and serum, reducing liver fatty degeneration, etc., thereby effectively preventing the occurrence, development, and deterioration of alcoholic fatty liver. It also relates to the use of a composition containing the Akkermansia muciniphila in the preparation or use of a medicine for preventing and treating alcoholic fatty liver.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The invention relates to the technical field of biological medicines, in particular to application of cinnamyl glycine in preparation of products for predicting or preventing and treating metabolism-related fatty liver diseases. The present invention is based on the prevention and / or treatment of metabolism-related fatty liver diseases and related conditions thereof on the basis of cinnamoylglycine. Experimental results show that the cinnamyl glycine can effectively predict the risk of metabolism-related fatty liver diseases and high-risk metabolism-related fatty hepatitis of community population; cinnamoylglycine intervention can effectively reduce the weight, the triglyceride level and the cholesterol level of mice induced by high-fat and high-cholesterol diet, and improve liver lipid deposition, inflammatory cell infiltration and liver cell ballooning. Cinnamoylglycine can improve metabolism-related fatty liver diseases by inhibiting FDPS expression and activity. The invention provides a new effective intervention thought and means for metabolism-related fatty liver diseases and related diseases thereof.

In an optional embodiment, a probiotic preparation for treating and alleviating metabolic and oxidative stress, inflammation and neurodegeneration and a method for using them are provided, including compositions, preparations, manufactured products and kits comprising them. In an optional embodiment, a probiotic preparation as provided herein comprises or is composed of any combination of Lactobacillus fermentum NCIMB 5221, Lactobacillus plantarum NCIMB 8826 and Bifidobacteria longum spp. infantis NCIMB 702255. In an optional embodiment, a probiotic preparation as provided herein is combined with Triphala. In an optional embodiment, a probiotic preparation as provided herein is used to treat metabolic diseases such as diabetes and obesity, inflammatory diseases such as IBD, IBS, arthritis; and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In alternative embodiments, the probiotic formulations provided herein are used to combat oxidative stress, reduce inflammation, lower blood and total glucose levels, lower triglyceride levels, and manage insulin resistance.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

The present invention provides an oral composition that can be used for anti-obesity, suppressing fat absorption, suppressing an increase in neutral fat, suppressing sugar absorption, suppressing an increase in blood sugar level, reducing body fat, or reducing BMI. [Solution] An oral composition containing gallic acid and ellagic acid, wherein the mass ratio of gallic acid to ellagic acid in the composition is gallic acid:ellagic acid = 1:0.01 to 0.7. The oral composition is preferably used for one or more purposes selected from anti-obesity, suppression of fat absorption, suppression of increase in triglyceride levels, suppression of sugar absorption, suppression of increase in blood glucose levels, reduction of body fat, and reduction of BMI. The oral composition preferably further contains chebulic acid.

The invention discloses a flaxseed composition capable of reducing triglyceride and facilitating obesity prevention and a preparation method of the flaxseed composition, and relates to the field of chemistry. According to the flaxseed composition capable of reducing triglyceride and contributing to obesity prevention and the preparation method of the flaxseed composition, the composition consists of the following components: 30-90% of flaxseeds; 10%-40% of tartary buckwheat; 0%-50% of oligosaccharide; the preparation method comprises the following steps: mixing the flaxseeds, the tartary buckwheat and the oligosaccharide according to the proportion in claim 1; crushing and screening to ensure that all the components are fully and uniformly mixed; and drying the mixture to obtain a final product. According to the composition, by reducing the triglyceride level, the risk of cardiovascular diseases is effectively reduced, and the overall metabolic state is improved; by promoting fat oxidation and improving insulin sensitivity, normal blood glucose and lipid levels can be maintained; the composition is helpful for reducing body weight and preventing obesity by regulating energy metabolism, reducing appetite and improving intestinal microbial environment.

The invention belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA as a biomarker or a target can be used for preparing a reagent for predicting, screening or diagnosing diseases and preparing a medicine for preventing or treating the diseases. The traditional Chinese medicine composition has the functions of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels in vivo, not influencing the high-density cholesterol level, reducing liver triglyceride deposition and liver fatty degeneration and improving atherosclerosis, the effect is definite and effective, and no adverse reaction exists. The invention provides a new biomarker and a treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The invention discloses an anti-obesity Leuconostoc mesenteroides strain and an application thereof. According to the present invention, a Leuconostoc pseudomesenteroides CU270 strain capable of reducing cholesterol content and triglyceride content is separated and identified from fermented pickled vegetables, the strain is preserved in Guangdong Microbial Culture Collection Center on November 4, 2024, and the preservation number is GDMCC NO.65413. The invention further discloses a preparation method of the Leuconostoc pseudomesenteroides CU270 strain capable of reducing cholesterol content and triglyceride content. Researches show that the CU270 strain has strong acid resistance, cholate resistance and oxidation resistance, and can significantly reduce the content of cholesterol and triglyceride. An obese animal model research finds that the strain can relieve obesity, reduce blood fat and blood sugar levels, improve blood fat rise caused by high-fat diet and relieve liver cell injury caused by high-fat diet, has no toxic or side effect, and provides a new thought for treatment of anti-obesity diseases.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The application discloses a plant lactobacillus gasseri strain capable of transforming ginsenoside and cassia glycoside, and application of the strain in lipid reduction and alleviation of fatty liver, and belongs to the fields of microbial technology, medicine and functional food. The core feature of the strain is that the strain can not only transform ginsenoside Rb1 into ginsenoside Rd with higher activity, but also transform cassia glycoside into cassia glycoside base, thereby improving the efficacy. The animal experiment proves that the strain and the corresponding substrate are combined to play a better role in lipid reduction and liver protection: the serum total cholesterol and triglyceride levels of high-fat diet mice can be effectively reduced, and the liver weight, liver lipid deposition and liver tissue fatty degeneration can be reduced and improved. The strain provides a new core strain and technical scheme for developing microecological preparations for preventing and / or assisting in treating hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases.

The present application belongs to the field of analytical chemistry and electrochemistry, and particularly relates to an electrochemical sensor, a preparation method and application thereof in detection of sweat triglyceride content. A wearable sensor is prepared based on C-ZIF-67 / KB nanocomposite material, the sensor realizes detection of sweat triglyceride for the first time, and it is verified that sweat triglyceride level has high correlation with blood triglyceride level (correlation coefficient is 0.813, n=35). Through verification of a commercial colorimetric analysis kit, the sensor obtains a high correlation coefficient of 0.853 in detection of sweat triglyceride, which shows excellent accuracy.

The invention discloses a medium-chain and long-chain fatty acid grease-probiotic composition and application thereof in regulating blood sugar and blood lipid, the composition comprises a grease component and a probiotic component, the grease component takes myristic acid as main fatty acid, MA accounts for 50-70% of the total amount of fatty acid in grease, and the grease component is compounded with medium-chain triglyceride and high-oleic-acid sunflower seed oil. And the probiotic component is bifidobacterium pseudocatenum, and the viable count of the bifidobacterium pseudocatenum is preferably 1 * 10 < 9 >-1 * 10 < 11 > CFU / g. Animal experiments verify that the composition can significantly reduce fasting blood-glucose, improve oral glucose tolerance damage and significantly reduce serum total cholesterol and triglyceride levels. Compared with single use of MA grease or single use of Bifidobacterium pseudocatenuicola, the composition provided by the invention shows a better comprehensive effect in the aspects of regulating blood sugar and blood fat, can be applied to functional foods, nutritional supplements and pharmaceutical preparations, and is used for preventing or assisting in improving abnormal glucose and lipid metabolism.

The present application relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has an effect of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis, and lowering triglyceride levels.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The present invention discloses an anti-ASGR1 monoclonal antibody and uses thereof. The present invention further discloses the use of an ASGR1 inhibitor, including an anti-ASGR1 monoclonal antibody, in combination with a second lipid-lowering drug to reduce total cholesterol and / or triglyceride levels in the blood and / or liver, or to treat and / or prevent cardiovascular disease. The present invention demonstrates that the combination of an ASGR1 inhibitor with a second lipid-lowering drug has a synergistic effect of lowering total cholesterol and triglycerides in serum and the liver.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.